Advanced Biomed Inc.
Close on Oct 19, 2026
- Market cap
- $6.51M
- P/E (TTM)
- 0.8
- Dividend yield
- –
About Advanced Biomed
Services-Medical Laboratories, SIC 8071
Advanced Biomed Inc. is a Nevada holding company that develops and operates FinTruth, an enterprise artificial intelligence financial verification platform. Following the divestment of its cancer research biomedical assets, the company focuses exclusively on AI technology applications. FinTruth evaluates AI-generated financial content, such as credit ratings, investment research, and financial reports, against source records and regulatory rules using a proprietary reasoning core. It offers numerical, logical, ontology, and narrative verification checks to generate auditable trails. The company targets enterprise clients, including commercial banks, securities firms, insurance carriers, asset managers, auditing practices, and financial technology companies.
The company delivers FinTruth through public cloud software-as-a-service, application programming interfaces, and on-premises deployments. Headquartered with primary engineering and research operations in Hong Kong, the firm employs 12 people across technical and administrative functions. It utilizes leased infrastructure from international cloud providers rather than owning physical data centers. The company also maintains a registered domain in the United States.
Summary of the business section of Advanced Biomed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Advanced Biomed Inc.
- Founded
- 2014
- Headquarters
- Reno, NV
- Address
- 401 Ryland St, Ste 200-A 89502
- Phone
- 86-21-20510823
- Website
- advb.ai
- Employees
- 12, Jun 30, 2026
- Industry
- Services-Medical Laboratories
- Incorporated in
- Nevada
- Fiscal year ends
- June 30
- Auditor
- WWC, P.C., San Mateo, California
Stock & identifiers
- Ticker
- ADVB
- Exchange
- Nasdaq
- IPO date
- Mar 6, 2025
- Shares outstanding
- 1M, Mar 31, 2026
- Public float
- $4.43M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, May 15, 2026; 1-for-20 reverse, Feb 20, 2026
- SEC CIK
- 1941029
- CUSIP
- 00752P203
- ISIN
- US00752P2039
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Advanced Biomed's leadership is listed in its proxy statement, last filed Jun 4, 2026.
Employees
Headcount reported in annual reports
“As of the date of this Report, we had 12 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 28, 2026 | Late filing | Notification of late filing |
| May 1, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 21, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 30, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 14, 2025 | Late filing | Notification of late filing |
| Sep 30, 2025 | Late filing | Notification of late filing |
| Jul 24, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 6, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 5, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |